Physician profile
Radha Menon
NPI 1427218122
$8,362.11
in general payments reported to CMS, 2019-2025
39 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $316 · 2021: $968 · 2022: $1,540 · 2023: $1,554 · 2024: $1,638 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,458 · Education: $99.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,457.59 |
| Education | $99.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,717.94 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $881.61 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $476.19 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $444.46 | 2020-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $433.45 | 2020-2025 | |
| Celgene Corporation | $426.05 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $338.49 | 2022-2025 | Dupixent |
| Medtronic, INC. | $324.51 | 2022-2024 | Interstim |
| Ardelyx, INC. | $300.13 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $236.96 | 2022-2025 | |
| Madrigal Pharmaceuticals | $225.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $218.13 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $168.75 | 2021-2024 | Linzess |
| Pfizer INC. | $168.13 | 2019-2025 | |
| Daiichi Sankyo INC. | $149.94 | 2019-2023 | Injectafer |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Menon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.